Angie Scherrer
Family · Newark, DENPI 1427784180
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 273 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 10.3% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$569
- AbbVie$569
- Lilly USA, LLC$522
- Abbott$488
- AstraZeneca$488
- Astellas Pharma US Inc$305
- plus $3K from 35 others
What the payments were for
- Food & beverage$5,40898%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $569 |
| AbbVie | 29 | $569 |
| Lilly USA, LLC | 29 | $522 |
| Abbott | 25 | $488 |
| AstraZeneca(2 entities) | 20 | $488 |
| Astellas Pharma US Inc | 12 | $305 |
| Corcept Therapeutics | 13 | $305 |
| Amgen | 14 | $296 |
| GSK | 16 | $247 |
| Novartis | 12 | $202 |
| Sanofi-aventis U.S. LLC | 5 | $155 |
| Pfizer | 8 | $132 |
| Merck | 7 | $121 |
| Boehringer Ingelheim | 7 | $115 |
| Insulet Corporation | 2 | $101 |
| Medtronic | 3 | $83 |
| Exact Sciences | 4 | $80 |
| Shield Therapeutics Inc | 3 | $76 |
| Xeris Pharmaceuticals, Inc. | 3 | $65 |
| Teva Pharmaceuticals USA, Inc. | 4 | $60 |
| Mannkind Corporation | 2 | $50 |
| Esperion Therapeutics, Inc. | 3 | $50 |
| Dexcom, Inc. | 1 | $41 |
| Bayer | 2 | $33 |
| Radius Health, Inc. | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Boston Scientific | 1 | $24 |
| Harmony Biosciences LLC | 1 | $24 |
| Sanofi US Services Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| BD | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $21 |
| Alk-abello, Inc | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $19 |
| Appliedvr Inc | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$5,508 in reported general payments places this provider in the 90th percentile of 523 family providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 15 | $17,142 |
| JardianceEmpagliflozin | 12 | $15,298 |
| Rosuvastatin Calcium | 79 | $1,983 |
| Atorvastatin Calcium | 108 | $1,549 |
| Omeprazole | 62 | $1,287 |
| Esomeprazole Magnesium | 15 | $1,057 |
| Levothyroxine Sodium | 90 | $920 |
| Amlodipine Besylate | 92 | $899 |
| Losartan Potassium | 67 | $749 |
| Ezetimibe | 25 | $742 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $725 |
| Escitalopram Oxalate | 34 | $649 |
| Gabapentin | 30 | $641 |
| Metformin Hcl | 66 | $545 |
| Olmesartan Medoxomil | 15 | $537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $522 | $17,14215 claims |
| Boehringer IngelheimJardiance | $115 | $15,29812 claims |
| AbbVieSynthroid | $569 | $53617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 523 family providers in Delaware.
Other family in Newark
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Melanie HiesterNewark$9K
- Samatha GrayNewark$9K
- Byron MayNewark$8K
- Clare MatisNewark$8K
- Christine MazzolaNewark$7K
- Kelsey FrybergerNewark$7K
- Colleen AllenNewark$7K
- Mallory KowalskiNewark$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.